CD24 a Potential Immunotherapeutic Target for Mantle-Cell Lymphoma: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Jimena Alvarez and Version 1 by Jimena Alvarez.

CD24 aThis entry is adapted from 10.3390/biomedicines10051175.

Ind its ligand Siglec-10 were described as an innatethe past decade, immune checkpoint in carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 expression and evaluating pro-phagocytic effects of CD24 antibody treatment in comparison to hallmark immune checkpoint CD47. In mantle cell lymphoma (MCL) and follicular lymphoma patients, high mRNA expression of CD24 correlated with poor overall survival, whereas CD47 expression did not. Conversely, CD24 expression did not correlate with survival in diffuse large B-cell lymphoma (DLBCL), whereas CD47 did. CD24 was also highly expressed on MCL cell lines, where treatment with CD24 antibody clones SN3 or ML5 potently induced phagocytosis, with SN3 yielding >90% removal of MCL cells and triggering phagocytosis of primary patient-derived MCL cells by autologous macrophages. Treatment with CD24 mAb was superior to CD47 mAb in MCL and was comparable in magnitude to the effect observed in carcinoma lines. Reversely, CD24 mAb treatment was less effective than CD47 mAb treatment in DLBCL. Finally, phagocytic activity of clone SN3 appeared at least partly independent of antibody-dependent cellular phagocytosis (ADCP), suggesting CD24/Siglec-10 checkpoint activity, whereas clone ML5 solely induced ADCP. In conclusion,hibitors (ICIs) that re-activate adaptive immunity have transformed the treatment paradigm in various cancer types. More recently, ICIs on innate immune cells have also gained prominence as therapeutic targets, being CD47 the hallmark ICI in the clinic. Lately, CD24 was also described as an innate immune checkpoint with apparent significance in several solid cancer types. In this entry, we discuss the role of CD24 is an immunoas a therapeutic target of potential clinical relevance for MCL, but not DLBCL, with a particular focus on mantle cell lymphoma (MCL) and diffuse-large B cell lymphoma (DLBCL). 

  • mantle cell lymphoma
  • CD24
  • immunotherapy
  • immune checkpoint
  • phagocytosis
Please wait, diff process is still running!

References

  1. Wenzhe Li; Huailei Ma; Jin Zhang; Ling Zhu; Chen Wang; Yanlian Yang; Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Scientific Reports 2017, 7, 1-15, 10.1038/s41598-017-14364-2.
  2. Safia N Salaria; Anna Means; Frank Revetta; Kamran Idrees; Eric Liu; Chanjuan Shi; Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.. American Journal of Clinical Pathology 2015, 144, 642-8, 10.1309/AJCPMZY5P9TWNJJV.
  3. Wookyeom Yang; Dasol Kim; Dae Kim; Kyung Choi; Dong Suh; Jae Kim; Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells. International Journal of Molecular Sciences 2021, 22, 5059, 10.3390/ijms22105059.
  4. Thomas A. Waldmann; Monoclonal Antibodies in Diagnosis and Therapy. Science 1991, 252, 1657-1662, 10.1126/science.2047874.
  5. Amira A. Barkal; Rachel E. Brewer; Maxim Markovic; Mark Kowarsky; Sammy A. Barkal; Balyn Zaro; Venkatesh Krishnan; Jason Hatakeyama; Oliver Dorigo; Layla J. Barkal; et al.Irving L. Weissman CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 2019, 572, 392-396, 10.1038/s41586-019-1456-0.
  6. Shiran Shapira; Dina Kazanov; Fatin Mdah; Hadas Yaakobi; Yair Herishanu; Chava Perry; Irit Avivi; Gilad Itchaki; Adi Shacham-Abulafia; Pia Raanani; et al.Mori Hay-LevyGal AigerJacob MashiahShahar Lev-AriNadir Arber Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies. Journal of Personalized Medicine 2021, 11, 724, 10.3390/jpm11080724.
  7. Katrina Lancaster-Shorts Et Al.; Follow; CD24 Expression in Follicular Lymphoma: An Alternative B-Cell Marker in Therapy Selected, Recurrent Lymphoma. Graduate Medical Education Research Journal 2020, 2, 65, 10.32873/unmc.dc.gmerj.2.1.065.
  8. Preetesh Jain; Michael Wang; Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. American Journal of Hematology 2019, 94, 710-725, 10.1002/ajh.25487.
  9. Kami Maddocks; Update on mantle cell lymphoma. Blood 2018, 132, 1647-1656, 10.1182/blood-2018-03-791392.
  10. P. Went; T. Dellas; C. Bourgau; R. Maurer; F. Augustin; A. Tzankov; S. Dirnhofer; Expressionsmuster und prognostische Bedeutung von CD24, p53 und p21 in Lymphomen. DMW - Deutsche Medizinische Wochenschrift 2004, 129, 2094-2099, 10.1055/s-2004-831850.
  11. Amira A. Barkal; Kipp Weiskopf; Kevin S. Kao; Sydney R. Gordon; Benyamin Rosental; Ying Y. Yiu; Benson M. George; Maxim Markovic; Nan G. Ring; Jonathan Tsai; et al.Kelly McKennaPo Yi HoRobin Z. ChengJames Y. ChenLayla J. BarkalAaron RingIrving L. WeissmanRoy L. Maute Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology 2017, 19, 76-84, 10.1038/s41590-017-0004-z.
  12. Kami Maddocks; Update on mantle cell lymphoma. Blood 2018, 132, 1647-1656, 10.1182/blood-2018-03-791392.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback